MorphoSys reports positive safety run-in Phase II L-MIND trial results of MOR208 to treat DLBCL

German biotechnology firm MorphoSys has completed the safety run-in phase of its Phase II L-MIND trial of MOR208 combined with lenalidomide, to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news